Drug factory · FDA FEI 3015793804
Abryl Laboratories Private Limited
VILLAGE BHAGWANPUR, TEHSIL DERA BASSI, District Sas Nagar, India
Serious problems, FDA action at FDA's last inspection, Sep 26, 2025.
Official Action Indicated: inspectors found significant problems and FDA recommended regulatory action, such as a warning letter or import alert.
1 drug inspection on record since 2025: 0 with no problems, 0 with problems fixed voluntarily, 1 with FDA action.
What it does, for whom
| Drug | Role | For | NDC |
|---|---|---|---|
| Daptomycin | Makes it | Biocon Pharma Inc. | 70377-093 |
| Potassium Cation | Makes it | Cipla USA., Inc. | 69097-055, 69097-077, 69097-078 |
| Regadenoson | Makes it | Indies Pharma Jamaica Limited, Kanchan Healthcare Inc, Marlex Pharmaceuticals, Inc. | 83032-001, 85742-012, 10135-803 |
FDA inspection history
| Ended | Result | Program | Problems noted |
|---|---|---|---|
| Sep 26, 2025 | Serious problems, FDA action | Drug Quality Assurance | — |
Registered with FDA for: manufacture.